Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRAF | P15056 | 19/20 | 0.57 |
| ▸ | KDR | P35968 | 5/20 | 0.57 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.52 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3639216 | 0.88 | BRAF (0.56) | BRAFKDRCYP2C9 | |
| SCHEMBL2192214 | 0.86 | FFAR1 (0.67) | BRAFKDRCYP2C9FFAR1 | |
| SCHEMBL2857455 | 0.85 | BRAF (0.68) | BRAFCYP2C9 | |
| SCHEMBL2851508 | 0.83 | BRAF (0.57) | BRAFKDRCYP2C9FFAR1 | |
| SCHEMBL3638532 | 0.80 | FFAR1 (0.47) | FFAR1 | |
| SCHEMBL2190254 | 0.80 | BRAF (0.57) | BRAFKDRCYP2C9 | |
| SCHEMBL2853720 | 0.80 | BRAF (0.54) | BRAFCYP2C9 | |
| SCHEMBL4287982 | 0.80 | BRAF (0.57) | BRAFKDRCYP2C9 | |
| SCHEMBL3640217 | 0.79 | BRAF (0.54) | BRAFKDRCYP2C9 | |
| SCHEMBL826296 | 0.78 | BRAF (0.60) | BRAFKDRCYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2162445-B1 | HETEROBICYCLIC COMPOUNDS AS KINASE INHIBITORS | TAKEDA PHARMACEUTICAL (JP) | 2013-11-27 | — | — | EP | disclosed |
| US-8304557-B2 | Fused heterocycle derivatives and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-11-06 | — | — | US | disclosed |
| EP-2162445-A1 | HETEROBICYCLIC COMPOUNDS AS KINASE INHIBITORS | Takeda Pharmaceutical Company Limited (JP) | 2010-03-17 | — | — | EP | disclosed |
| US-20090163488-A1 | FUSED HETEROCYCLE DERIVATIVES AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-06-25 | — | — | US | disclosed |
| WO-2008150015-A1 | HETEROBICYCLIC COMPOUNDS AS KINASE INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-12-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090163488-A1 | FUSED HETEROCYCLE DERIVATIVES AND USE THEREOF | NOX3, NOX5, ZYX | BRAF 1364/4885KDR 2311/4885CYP2C9 1211/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.